Israeli Parkinson's specialist Intec Pharma and drug delivery device maker EyeGate aim to debut on the Nasdaq this week for a combined $51 million.
RNAi specialist Alnylam initiated Phase I/II trials of its candidate to treat AAT deficiency-associated liver disease (alpha-1 liver disease).
Researchers at MIT and Massachusetts General Hospital have designed an expanding pill that can be easily swallowed but can remain in the stomach potentially for months without obstructing normal gastrointestinal function.
Folding DNA into new, functional shapes isn't a new technique, but researchers at Arizona State University have demonstrated novel design methods that allow them an amount of control over the genetic substance never seen before, creating new three-dimensional shapes that could ultimately be used in drug delivery.
Germany's leon-nanodrugs GmbH announced the closure of its €18.5 ($20.4 million) Series A preferred stock offering. The company develops oral and parenteral reformulations of generic active pharmaceutical ingredients using its patented MJR nanotechnology platform.
Ra Pharma received $58.5 million from a mix of strategic and VC investors to take on Alexion's intravenously infused orphan drug Soliris with a cheaper, subcutaneously delivered alternative.
Although fancy technology is a big draw in drug delivery, the simple pill remains an allure, at least as a replacement for dreaded needles or cumbersome intravenous infusions.
New work from researchers at UCLA is shedding light on the delivery of glucose to tumor cells, particularly in pancreatic and prostate cancers. The research could offer new diagnostic procedures for detecting these cancers and, down the road, the use of inhibitors to cut down the amount of glucose delivered to the tumors, slowing down their growth.
The FDA granted Delcath Systems orphan drug designation for its drug/delivery device combination product to treat liver cancer, including a rare form that affects fewer than 200,000 people in the U.S. The indication to treat intrahepatic cholangiocarcinoma will now receive favorable treatment from the FDA
Researchers at Washington University iin St. Louis and the University of Illinois at Urbana-Champaign have overcome a common problem in drug delivery to the brain, which is to get the therapies to target certain brain circuits without accidentally affecting other parts of the brain or body.
Purdue University researchers are developing a "smart" capsule to deliver drugs directly to the large intestine, bypassing the stomach and small intestine. It could have application to the treatment of irritable bowel syndrome, Crohn's disease and fighting the life-threatening bacteria Clostridium difficile, all conditions that affect the large intestine.
Novo Nordisk relies on improvements in its drug delivering injection pens to maintain and gain the market share of its injectables. To that end, the company just received FDA approval for its FlexPro PenMate to conceal the needle of injection pens used to administer its Norditropin for children and adults with growth hormone deficiency. It will be made commercially available in the second half of the year.
Anacor Pharmaceuticals' topical treatment for eczema easily beat placebo in two Phase III trials, sending the biotech's share soaring and setting the stage for FDA application in the first of half of 2016.
A recent paper in Future Science provides an overview of clinical and preclinical nano- and microparticles and bubbles for carrying drugs to treat ischemic heart disease and stroke, with a goal of decreasing the rate of drugs' degradation in the blood and increasing the amount reaching the blood clot (or thrombus).
German researchers have come up with an approach for chemotherapy that would allow the medication to be activated inside a patient when hit with light.
Paris-based Eligo Bioscience pulled in €2 million in first-round financing to fund its ongoing efforts to target bacterial infections while sparing the healthy cells nearby. The technology is based on the booming CRISPR gene editing model, and the company is developing two lead candidates.
Valeant Pharmaceuticals will commercialize and manufacture a delivery system and reformulated, topically active corticosteroid to treat uveitis developed EyeGate.
Neos Therapeutics, a Dallas-area maker of extended-release formulations for ADHD that disintegrate in the mouth, announced that it aims to raise $60 million on the Nasdaq in an IPO planned for next week. The company expects to sell 4 million shares at $14 to $16 a pop.
Allergan is acquiring the startup Oculeve for $125 million. Oculeve's lead program is a clinical-stage dry-eye implant designed to stimulate natural tear production, which could replace the need for inconvenient lubricating eye drops.
Many sea creatures, like shrimp, employ bioluminescence in the dark depths of the ocean, and scientists at the Harry Perkins Institute of Medical Research are testing the proteins involved in that process to determine the way drugs interact with cells and help discover more efficient drug delivery methods.